These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

530 related articles for article (PubMed ID: 27250788)

  • 1. BET Bromodomain as a Target of Epigenetic Therapy.
    Noguchi-Yachide T
    Chem Pharm Bull (Tokyo); 2016; 64(6):540-7. PubMed ID: 27250788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Bromodomain and Extra-Terminal Domain (BET) Family: Functional Anatomy of BET Paralogous Proteins.
    Taniguchi Y
    Int J Mol Sci; 2016 Nov; 17(11):. PubMed ID: 27827996
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bromodomains: Structure, function and pharmacology of inhibition.
    Ferri E; Petosa C; McKenna CE
    Biochem Pharmacol; 2016 Apr; 106():1-18. PubMed ID: 26707800
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bromodomain inhibitors and cancer therapy: From structures to applications.
    Pérez-Salvia M; Esteller M
    Epigenetics; 2017 May; 12(5):323-339. PubMed ID: 27911230
    [TBL] [Abstract][Full Text] [Related]  

  • 5. BET Bromodomain Inhibitors: Novel Design Strategies and Therapeutic Applications.
    To KKW; Xing E; Larue RC; Li PK
    Molecules; 2023 Mar; 28(7):. PubMed ID: 37049806
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery.
    Fu LL; Tian M; Li X; Li JJ; Huang J; Ouyang L; Zhang Y; Liu B
    Oncotarget; 2015 Mar; 6(8):5501-16. PubMed ID: 25849938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Affinity map of bromodomain protein 4 (BRD4) interactions with the histone H4 tail and the small molecule inhibitor JQ1.
    Jung M; Philpott M; Müller S; Schulze J; Badock V; Eberspächer U; Moosmayer D; Bader B; Schmees N; Fernández-Montalván A; Haendler B
    J Biol Chem; 2014 Mar; 289(13):9304-19. PubMed ID: 24497639
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bromodomains and their pharmacological inhibitors.
    Gallenkamp D; Gelato KA; Haendler B; Weinmann H
    ChemMedChem; 2014 Mar; 9(3):438-64. PubMed ID: 24497428
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Epigenetic blockade of neoplastic transformation by bromodomain and extra-terminal (BET) domain protein inhibitor JQ-1.
    Zhang C; Su ZY; Wang L; Shu L; Yang Y; Guo Y; Pung D; Bountra C; Kong AN
    Biochem Pharmacol; 2016 Oct; 117():35-45. PubMed ID: 27520485
    [TBL] [Abstract][Full Text] [Related]  

  • 10. BET bromodomain inhibitors show anti-papillomavirus activity in vitro and block CRPV wart growth in vivo.
    Morse MA; Balogh KK; Brendle SA; Campbell CA; Chen MX; Furze RC; Harada IL; Holyer ID; Kumar U; Lee K; Prinjha RK; Rüdiger M; Seal JT; Taylor S; Witherington J; Christensen ND
    Antiviral Res; 2018 Jun; 154():158-165. PubMed ID: 29653131
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The exploitation of FRET probes to track bromodomain/histone interactions in cells for bromodomain inhibitors.
    Sasaki K; Yoshida M
    Drug Discov Today Technol; 2016 Mar; 19():51-56. PubMed ID: 27769358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disrupting Acetyl-lysine Interactions: Recent Advance in the Development of BET Inhibitors.
    Zhang F; Ma S
    Curr Drug Targets; 2018; 19(10):1148-1165. PubMed ID: 29189147
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epigenetic Targets and their Inhibitors in Cancer Therapy.
    Zhao L; Duan YT; Lu P; Zhang ZJ; Zheng XK; Wang JL; Feng WS
    Curr Top Med Chem; 2018; 18(28):2395-2419. PubMed ID: 30582481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the cancer epigenome: synergistic therapy with bromodomain inhibitors.
    Ramadoss M; Mahadevan V
    Drug Discov Today; 2018 Jan; 23(1):76-89. PubMed ID: 28943305
    [TBL] [Abstract][Full Text] [Related]  

  • 15. JQ1, an inhibitor of the epigenetic reader BRD4, suppresses the bidirectional MYC-AP4 axis via multiple mechanisms.
    Choi SK; Hong SH; Kim HS; Shin CY; Nam SW; Choi WS; Han JW; You JS
    Oncol Rep; 2016 Feb; 35(2):1186-94. PubMed ID: 26573731
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting epigenetic reader and eraser: Rational design, synthesis and in vitro evaluation of dimethylisoxazoles derivatives as BRD4/HDAC dual inhibitors.
    Zhang Z; Hou S; Chen H; Ran T; Jiang F; Bian Y; Zhang D; Zhi Y; Wang L; Zhang L; Li H; Zhang Y; Tang W; Lu T; Chen Y
    Bioorg Med Chem Lett; 2016 Jun; 26(12):2931-2935. PubMed ID: 27142751
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BET bromodomain inhibitors: a patent review.
    Garnier JM; Sharp PP; Burns CJ
    Expert Opin Ther Pat; 2014 Feb; 24(2):185-99. PubMed ID: 24261714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Chemical modulators for epigenome reader domains as emerging epigenetic therapies for cancer and inflammation.
    Zaware N; Zhou MM
    Curr Opin Chem Biol; 2017 Aug; 39():116-125. PubMed ID: 28689146
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting BET bromodomains for cancer treatment.
    Jung M; Gelato KA; Fernández-Montalván A; Siegel S; Haendler B
    Epigenomics; 2015; 7(3):487-501. PubMed ID: 26077433
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.